These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 11115955

  • 21. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.
    Gao Q, Gu Z, Salomon H, Nagai K, Parniak MA, Wainberg MA.
    Arch Virol; 1994; 136(1-2):111-22. PubMed ID: 8002779
    [Abstract] [Full Text] [Related]

  • 22. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells.
    Benbrik E, Chariot P, Bonavaud S, Ammi-Saïd M, Frisdal E, Rey C, Gherardi R, Barlovatz-Meimon G.
    J Neurol Sci; 1997 Jul; 149(1):19-25. PubMed ID: 9168161
    [Abstract] [Full Text] [Related]

  • 23. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [Abstract] [Full Text] [Related]

  • 24. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds.
    Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR.
    Lancet; 1994 May 21; 343(8908):1292. PubMed ID: 7910296
    [No Abstract] [Full Text] [Related]

  • 25. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.
    Gao WY, Johns DG, Chokekuchai S, Mitsuya H.
    Proc Natl Acad Sci U S A; 1995 Aug 29; 92(18):8333-7. PubMed ID: 7667290
    [Abstract] [Full Text] [Related]

  • 26. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.
    García-Lerma JG, Gerrish PJ, Wright AC, Qari SH, Heneine W.
    J Virol; 2000 Oct 29; 74(20):9339-46. PubMed ID: 11000201
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes.
    Aquaro S, Perno CF, Balestra E, Balzarini J, Cenci A, Francesconi M, Panti S, Serra F, Villani N, Caliò R.
    J Leukoc Biol; 1997 Jul 29; 62(1):138-43. PubMed ID: 9226005
    [Abstract] [Full Text] [Related]

  • 28. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul 29; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [Abstract] [Full Text] [Related]

  • 29. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea.
    Boelaert JR, Sperber K, Piette J.
    AIDS Res Hum Retroviruses; 1999 Sep 20; 15(14):1241-7. PubMed ID: 10505672
    [Abstract] [Full Text] [Related]

  • 30. Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus.
    Bridges EG, Dutschman GE, Gullen EA, Cheng YC.
    Biochem Pharmacol; 1996 Mar 22; 51(6):731-6. PubMed ID: 8602867
    [Abstract] [Full Text] [Related]

  • 31. The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea.
    Boelaert JR, Sperber K, Piette J.
    Biochem Pharmacol; 2001 Jun 15; 61(12):1531-5. PubMed ID: 11377382
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
    Palmer S, Harmenberg J, Cox S.
    Antimicrob Agents Chemother; 1996 May 15; 40(5):1285-8. PubMed ID: 8723486
    [Abstract] [Full Text] [Related]

  • 36. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.
    Chokekijchai S, Shirasaka T, Weinstein JN, Mitsuya H.
    Antiviral Res; 1995 Sep 15; 28(1):25-38. PubMed ID: 8585758
    [Abstract] [Full Text] [Related]

  • 37. Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs.
    Ratner L, Vander Heyden N.
    AIDS Res Hum Retroviruses; 1993 Apr 15; 9(4):291-7. PubMed ID: 8390276
    [Abstract] [Full Text] [Related]

  • 38. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.
    Antivir Chem Chemother; 2000 Jul 15; 11(4):291-301. PubMed ID: 10950391
    [Abstract] [Full Text] [Related]

  • 39. Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.
    Dornsife RE, St Clair MH, Huang AT, Panella TJ, Koszalka GW, Burns CL, Averett DR.
    Antimicrob Agents Chemother; 1991 Feb 15; 35(2):322-8. PubMed ID: 1708977
    [Abstract] [Full Text] [Related]

  • 40. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M.
    AIDS; 1998 Jun 18; 12(9):1015-20. PubMed ID: 9662197
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.